Document is current
Any future updates will be listed below
-
Authors
Stechele, Matthias
Link, Henrike
Hirner-Eppeneder, Heidrun
Alunni-Fabbroni, Marianna
Wildgruber, Moritz
Salvermoser, Lukas
Corradini, Stefanie
Schinner, Regina
Ben Khaled, Najib
Rössler, Daniel
Galun, Eithan
Goldberg, Shraga Nahum
Ricke, Jens
Kazmierczak, Philipp Maximilian
-
Clinical Trials BETA
Clinical trials referenced in this document:
drks00010587 at German Clinical Trials RegisterDocuments that mention this clinical trial
Circulating miR-21 as a prognostic biomarker in HCC treated by CT-guided high-dose rate brachytherapy
https://doi.org/10.1186/s13014-023-02316-2
-
Funding
Funding for this research was provided by:
Bayer Science & Education Foundation
MOST - DKFZ
ISF collaboration with Canada
the personalised medicine ISF grant
Deutsche Forschungsgemeinschaft (SFB841)
ERC advance - GA (No. 786575 – RxmiRcanceR)
Israeli Science Foundation (904/2020)
Universitätsklinik München
- License Information
-
More Information
Article History
Received: 18 February 2023
Accepted: 5 July 2023
First Online: 28 July 2023
Declarations
:
: In this monocentric clinical study, we analyzed prospectively acquired data of 24 patients from the “ESTIMATE” patient cohort (Studiennummer: DRKS00010587, Deutsches Register Klinischer Studien). Ethical approval was provided by the ethics committee “Ethikkommission bei der LMU München” (reference number “17-346”) on June 20, 2017 and August 26, 2020.
: Patients provided written informed consent for both the local ablative treatment and study inclusion.
: The work of Eithan Galun was supported by grants from MOST - DKFZ, the ISF collaboration with Canada, the personal ISF, the personalised medicine ISF grant, the Deutsche Forschungsgemeinschaft, Bonn, Germany (SFB841) and the ERC advance - GA No. 786575 – RxmiRcanceR. The work of Shraga Nahum Goldberg was supported by Grant 904/2020 from Israeli Science Foundation. The work of Henrike Link was supported by funding from the Bayer Science & Education Foundation.
